PART I Overview We are a clinical-stage specialty pharmaceutical company developing and commercializing therapies for the treatment of retinal diseases. We are developing KIO-301, with an initial focus on patients with later stages of vision loss due to retinitis pigmentosa (collectively including any and all sub-forms, "RP"). KIO-301 is a potential vision-restoring small molecule that acts as a photoswitch specifically created to restore vision in patients with inherited and age-related degener...
Q2 FY2026 — expected 2026-08-14
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-25 | 2025-12-31 | 0001372514-26-000024 | EDGAR | 65K words |
| 2025-03-25 | 2024-12-31 | 0001372514-25-000012 | EDGAR | — |
| 2024-03-25 | 2023-12-31 | 0001372514-24-000026 | EDGAR | — |
| 2023-03-23 | 2022-12-31 | 0001372514-23-000050 | EDGAR | — |
| 2022-04-15 | 2021-12-31 | 0001410578-22-000925 | EDGAR | — |
| 2021-03-25 | 2020-12-31 | 0001104659-21-041515 | EDGAR | — |
| 2020-03-04 | 2019-12-31 | 0001104659-20-029162 | EDGAR | — |
| 2019-03-01 | 2018-12-31 | 0001144204-19-011634 | EDGAR | — |
| 2018-03-02 | 2017-12-31 | 0001144204-18-012542 | EDGAR | — |
| 2017-02-23 | 2016-12-31 | 0001144204-17-010635 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-07 | 2026-06-30 | 0001372514-26-000074 | EDGAR | — |
| 2025-11-07 | 2025-09-30 | 0001372514-25-000078 | EDGAR | 19K words |
| 2025-08-08 | 2025-06-30 | 0001372514-25-000061 | EDGAR | — |
| 2025-05-09 | 2025-03-31 | 0001372514-25-000044 | EDGAR | — |
| 2024-11-08 | 2024-09-30 | 0001372514-24-000120 | EDGAR | — |
| 2024-08-09 | 2024-06-30 | 0001372514-24-000104 | EDGAR | — |
| 2024-05-10 | 2024-03-31 | 0001372514-24-000053 | EDGAR | — |
| 2023-11-09 | 2023-09-30 | 0001372514-23-000158 | EDGAR | — |
| 2023-08-08 | 2023-06-30 | 0001372514-23-000117 | EDGAR | — |
| 2023-05-09 | 2023-03-31 | 0001372514-23-000069 | EDGAR | — |
| 2022-11-09 | 2022-09-30 | 0001410578-22-003035 | EDGAR | — |
| 2022-08-12 | 2022-06-30 | 0001410578-22-002336 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-07 | 0001372514-26-000075 | EDGAR | — |
| 2026-04-02 | 0001372514-26-000028 | EDGAR | 1K words |
| 2026-03-25 | 0001372514-26-000025 | EDGAR | — |
| 2025-11-07 | 0001372514-25-000079 | EDGAR | — |
| 2025-08-13 | 0001372514-25-000068 | EDGAR | — |
| 2025-08-08 | 0001372514-25-000064 | EDGAR | — |
| 2025-06-04 | 0001372514-25-000053 | EDGAR | — |
| 2025-06-03 | 0001372514-25-000050 | EDGAR | — |
| 2025-05-09 | 0001372514-25-000045 | EDGAR | — |
| 2025-03-25 | 0001372514-25-000014 | EDGAR | — |
258 total filings indexed. 226 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001372514 |
| Ticker | KPRX |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Website | https://www.kiorapharma.com |
| Listed | 2015-02-13 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/KPRX (~200 tokens, structured JSON with cryptographic provenance)